New drug combo tested to shield transplant patients from dangerous rejection
NCT ID NCT03320642
Summary
This study tested whether adding the experimental drug itacitinib to standard preventive medications could better protect patients from graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. It involved 84 participants who were eligible for a reduced-intensity transplant. The main goals were to see if the combination was safe and if it helped patients' blood counts recover properly after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anschutz Cancer Pavilion - University of Colorado
Aurora, Colorado, 80045, United States
-
Azienda Ospedaliera San Gerardo Di Monza
Monza, 20900, Italy
-
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii)
Bergamo, 24127, Italy
-
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
Nantes, 44093, France
-
Chru de Lille Hopital Claude Huriez
Lille, 59037, France
-
Chu Vandoeuvre-Les-Nancy, Hopital Brabois
Vandœuvre-lès-Nancy, 54500, France
-
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
Pavia, 27100, Italy
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Puerta de Hierro
Majadahonda, 28222, Spain
-
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
University of Maryland - Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.